FDA Approves First Freeze-Dried Plasma, Mounjaro for Heart Risk, First Oral Dermatomyositis Drug
The FDA has cleared three notable healthcare developments: Ezplaz Freeze Dried Plasma, a new cardiovascular-risk indication for Mounjaro (tirzepatide), and Lisraya (brepocitinib), the first oral treatment specifically indicated for adult dermatomyositis.
Ezplaz, licensed July 29, is the first freeze-dried plasma product licensed in the United States. Unlike conventional frozen plasma, it can be stored at room temperature and reconstituted in about 2.5 minutes. The FDA says it is intended for adults who need plasma when other products are unavailable: including certain bleeding and massive-transfusion situations. That could be especially valuable in rural hospitals, disaster zones, combat areas, and other settings where reliable refrigeration is limited. FDA
For adults with type 2 diabetes and high cardiovascular risk, Mounjaro is now approved to reduce the risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke. The decision followed the SURPASS-CVOT trial, which compared tirzepatide with dulaglutide. Medscape Related ScienceAlert reporting has also examined tirzepatide’s broader health effects, underscoring why patients should discuss benefits and risks with a clinician.
Finally, Lisraya was approved August 27 for adults with dermatomyositis, a rare autoimmune disease affecting muscles and skin. The once-daily TYK2/JAK1 inhibitor improved disease activity in the phase 3 VALOR trial, but carries serious safety warnings. FDA BioSpace
These health developments are part of the lifestyle trends shaping conversations about emergency readiness, chronic disease, and personalized care. Neighbor next step: verify medication news through the FDA, your pharmacist, or your healthcare provider before changing treatment. What medical breakthrough would make the biggest difference in your community?
